

SECTION 1 : PRODUCT AND COMPANY IDENTIFICATION

Product Name: **Glucagon for Injection**

Product Description: Glucagon for Injection is a sterile, lyophilized white powder in a 3 mL vial. The reconstituted solution contains 1 mg of glucagon as hydrochloride per mL and lactose monohydrate (107 mg). Glucagon for Injection is supplied at pH 1.7 - 3.5 and is soluble in water.

Manufacturer Name: Fresenius Kabi USA, LLC

Address: Three Corporate Drive
Lake Zurich, Illinois 60047

General Phone Number: (847) 550-2300

Customer Service Phone Number: (888) 386-1300

Health Issues Information: (800) 551-7176

HMIS	
Health Hazard	1
Fire Hazard	1
Reactivity	1
Personal Protection	X

SECTION 2 : COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS#	Ingredient Percent	EC Num.
Glucagon	16941-32-5	0.93 by weight	
Lactose Monohydrate	5989-81-1	99.07 by weight	
Sodium Hydroxide	1310-73-2	As needed to adjust pH	
Hydrochloric Acid	7647-01-0	As needed to adjust pH	

SECTION 3 : HAZARDS IDENTIFICATION

Emergency Overview: This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.

Route of Exposure: Inhalation, Ingestion, Eye contact, Skin Absorption, Injection.

Potential Health Effects:

Eye: Contact with eyes may cause irritation.

Skin: May cause skin irritation.

Inhalation: May cause irritation of respiratory tract.

Ingestion: May cause irritation.

Signs/Symptoms: Adverse reactions from therapeutic doses include: nausea and vomiting may occur after use of glucagon. Hypersensitivity reactions, abdominal pain, hypotension, tachycardia, and hypokalemia have also been reported. A person may exhibit a rapid heart rate and nausea and vomiting. May increase blood pressure.

Target Organs: Liver, gastrointestinal system and the cardiovascular system

Aggravation of Pre-Existing Conditions: Individuals who have insulinoma and/or pheochromocytoma may experience an allergic reaction to Glucagon.

SECTION 4 : FIRST AID MEASURES

Eye Contact: Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of the eyes by separating the eyelids with fingers. Get immediate medical attention.

Skin Contact: Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes. Get medical attention if irritation develops or persists.

Inhalation: If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Seek immediate medical attention.

Ingestion: If conscious, flush mouth out with water immediately. Call a physician or poison control center immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person.

Other First Aid: For Adverse Event Information, please call (800) 551-7176.

SECTION 5 : FIRE FIGHTING MEASURES

Flash Point: Not established.

Flash Point Method:	Not established.
Auto Ignition Temperature:	Not established.
Lower Flammable/Explosive Limit:	Not established.
Upper Flammable/Explosive Limit:	Not established.
Fire Fighting Instructions:	Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible, contain fire run-off water.
Extinguishing Media:	Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires involving this material. Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Protective Equipment:	As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent) and full protective gear.
Hazardous Combustion Byproducts:	Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of combustion.

SECTION 6 : ACCIDENTAL RELEASE MEASURES

Personal Precautions:	Evacuate area and keep unnecessary and unprotected personnel from entering the spill area. Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as listed in Section 8.
Environmental Precautions:	Avoid runoff into storm sewers, ditches, and waterways.
Methods for containment:	Contain spills with an inert absorbent material such as soil, sand or oil dry.
Methods for cleanup:	Absorb spill with inert material (e.g., dry sand or earth), then place in a chemical waste container. After removal, flush spill area with soap and water to remove trace residue.

SECTION 7 : HANDLING and STORAGE

Handling:	When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes. Use with adequate ventilation. Use only in accordance with directions.
Storage:	The package containing Glucagon for Injection vials may be stored up to 24 months at 20° to 25° C (68° to 77° F) [see USP Controlled Room Temperature] prior to reconstitution. Do not freeze. Keep in original package to protect from light.
Work Practices:	Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower.
Hygiene Practices:	Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

SECTION 8 : EXPOSURE CONTROLS, PERSONAL PROTECTION - EXPOSURE GUIDELINES

Engineering Controls:	General ventilation is sufficient if this product is being used in a controlled medical setting (clinic, hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended exposure limits.
Eye/Face Protection:	Chemical splash goggles. Wear a face shield also when splash hazard exist.
Skin Protection Description:	Protective laboratory coat, apron, or disposable garment recommended.
Hand Protection Description:	Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data. Nitrile rubber or natural rubber gloves are recommended.
Respiratory Protection:	No personal respiratory protective equipment is normally required when this product is being used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site (http://www.cdc.gov/niosh/npptl/topics/respirators/) for a list of respirator types and approved suppliers.
Other Protective:	Consult with local procedures for selection, training, inspection and maintenance of the personal protective equipment.

EXPOSURE GUIDELINES

Sodium Hydroxide :	
Guideline ACGIH:	TLV-STEL: C 2 mg/m ³
Hydrochloric Acid :	
Guideline ACGIH:	TLV-STEL: C 2 ppm
Guideline OSHA:	PEL-Ceiling/Peak: 5 ppm

SECTION 9 : PHYSICAL and CHEMICAL PROPERTIES

Physical State:	Solid or powder.
Color:	White
Boiling Point:	Not established.

Melting Point:	Not established.
Solubility:	Soluble in water.
Vapor Density:	Not established.
Vapor Pressure:	Not established.
Percent Volatile:	Not established.
pH:	1.7 - 3.5 (Reconstituted solution)
Flash Point:	Not established.
Flash Point Method:	Not established.
Auto Ignition Temperature:	Not established.

SECTION 10 : STABILITY and REACTIVITY

Chemical Stability:	Stable under normal temperatures and pressures.
Hazardous Polymerization:	Not reported.
Conditions to Avoid:	Protect from freezing. Protect from light.

SECTION 11 : TOXICOLOGICAL INFORMATION

Glucagon :

Other Toxicological Information:	Subcutaneous - Rat : 20 mg/kg [No death or toxicity] Intravenous - Mouse : 300 mg/kg [no deaths, reduced activity, labored breathing, drooping eyelids] Intravenous - Rat : 20 mg/kg [no deaths, incoordination, reduced activity.](Manufacturer)
----------------------------------	---

Sodium Hydroxide :

Eye:	Administration into the eye - Rabbit Standard Draize test: 400 ug [Mild] Administration into the eye - Rabbit Standard Draize test: 1 % [Severe] Administration into the eye - Rabbit Standard Draize test: 50 ug/24H [Severe] Administration into the eye - Rabbit Standard Draize test: 1 mg/24H [Severe] Administration into the eye - Rabbit Rinsed with water: 1 mg/30S [Severe] (RTECS)
------	---

Other Toxicological Information:	Intraperitoneal - Mouse LD50 - Lethal dose, 50 percent kill: 40 mg/kg [Details of toxic effects not reported other than lethal dose value] (RTECS)
----------------------------------	--

Hydrochloric Acid :

Eye:	Administration into the eye - Rabbit Rinsed with water: 5 mg/30S [Mild] (RTECS)
------	---

Inhalation:	Inhalation - Rat LC50 - Lethal concentration, 50 percent kill: 3124 ppm/1H [Sense Organs and Special Senses (Olfaction) - effect, not otherwise specified Sense Organs and Special Senses (Eye) - Iritis] Inhalation - Rat LC50 - Lethal concentration, 50 percent kill: 45000 mg/m ³ /5M [Lungs, Thorax, or Respiration - Acute pulmonary edema] Inhalation - Rat LC50 - Lethal concentration, 50 percent kill: 8300 mg/m ³ /30M [Lungs, Thorax, or Respiration - Acute pulmonary edema] Inhalation - Rat LC50 - Lethal concentration, 50 percent kill: 60938 mg/m ³ /5M [Lungs, Thorax, or Respiration - Acute pulmonary edema] Inhalation - Rat LC50 - Lethal concentration, 50 percent kill: 7004 mg/m ³ /30M [Lungs, Thorax, or Respiration - Acute pulmonary edema] Inhalation - Rat LC50 - Lethal concentration, 50 percent kill: 3700 ppm/30M [Details of toxic effects not reported other than lethal dose value] (RTECS)
-------------	---

Other Toxicological Information:	Intraperitoneal - Mouse LD50 - Lethal dose, 50 percent kill: 40142 ug/kg [Details of toxic effects not reported other than lethal dose value] Subcutaneous - Human TDLo - Lowest published toxic dose: 0.043 mL/kg [Vascular - Acute arterial occlusion Musculoskeletal - Other changes] (RTECS)
----------------------------------	---

SECTION 12 : ECOLOGICAL INFORMATION

Ecotoxicity:	No ecotoxicity data was found for the product.
Environmental Stability:	No environmental information found for this product.

SECTION 13 : DISPOSAL CONSIDERATIONS

Waste Disposal:	Dispose of in accordance with Local, State, Federal and Provincial regulations.
-----------------	---

SECTION 14 : TRANSPORT INFORMATION

DOT Shipping Name:	Not Regulated.
DOT UN Number:	Not Regulated.
IATA Shipping Name:	Non regulated.
IATA UN Number:	Non regulated.

IMDG UN Number : Non regulated.

IMDG Shipping Name : Non regulated.

SECTION 15 : REGULATORY INFORMATION

Sodium Hydroxide :

TSCA Inventory Status: Listed

Canada DSL: Listed

Hydrochloric Acid :

TSCA Inventory Status: Listed

Section 302 EHS: EPCRA (SARA Title III) Section 302 (40 CFR Part 355) Extremely Hazardous Substances (EHS) Threshold Planning Quantity (TPQ) in pounds.: 500

Section 313: EPCRA - 40 CFR Part 372 - (SARA Title III) Section 313 Listed Chemical.

Canada DSL: Listed

SECTION 16 : ADDITIONAL INFORMATION

Label Hazard Warning: None.

Label Precautions: None.

HMIS Ratings:

HMIS Health Hazard: 1

HMIS Fire Hazard: 1

HMIS Reactivity: 1

HMIS Personal Protection: X

SDS Creation Date: May 11, 2015

SDS Revision Date: May 11, 2015

Disclaimer:

The information contained herein pertains to this material. It is the responsibility of each individual party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Fresenius-Kabi assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data sheet does not constitute the guaranty or specifications of the product.

Copyright© 1996-2015 Actio Corporation. All Rights Reserved.